轻度认知障碍患者短期记忆受损时接触系统激活增加。
Increased Contact System Activation in Mild Cognitive Impairment Patients with Impaired Short-Term Memory.
机构信息
Patricia and John Rosenwald Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY, USA.
出版信息
J Alzheimers Dis. 2020;77(1):59-65. doi: 10.3233/JAD-200343.
Abstract
An activated plasma contact system is an abnormality observed in many Alzheimer's disease (AD) patients. Since mild cognitive impairment (MCI) patients often develop AD, we analyzed the status of contact system activation in MCI patients. We found that kallikrein activity, high molecular weight kininogen cleavage, and bradykinin levels- measures of contact system activation- were significantly elevated in MCI patient plasma compared to plasma from age- and education-matched healthy individuals. Changes were more pronounced in MCI patients with impaired short-term recall memory, indicating the possible role of the contact system in early cognitive changes.
摘要
激活的血浆接触系统是许多阿尔茨海默病（AD）患者中观察到的异常现象。由于轻度认知障碍（MCI）患者经常发展为 AD，因此我们分析了 MCI 患者接触系统激活的状态。我们发现激肽释放酶活性、高分子量激肽原裂解和缓激肽水平——接触系统激活的衡量标准——在 MCI 患者血浆中明显高于年龄和教育程度匹配的健康个体的血浆。在短期回忆记忆受损的 MCI 患者中，变化更为明显，表明接触系统可能在早期认知变化中起作用。
相似文献
1
Increased Contact System Activation in Mild Cognitive Impairment Patients with Impaired Short-Term Memory.
J Alzheimers Dis. 2020;77(1):59-65. doi: 10.3233/JAD-200343.
2
Memory impairment, in mild cognitive impairment without significant cerebrovascular disease, predicts progression to Alzheimer's disease.
Dement Geriatr Cogn Disord. 2012;33(4):240-4. doi: 10.1159/000339159. Epub 2012 Jun 11.
3
Forgetting Rates on the Recency Portion of a Word List Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease.
J Alzheimers Dis. 2020;73(4):1295-1304. doi: 10.3233/JAD-190509.
4
The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin.
Biol Chem. 2002 Oct;383(10):1633-43. doi: 10.1515/BC.2002.184.
5
Lowered performance in working memory and attentional sub-processes are most prominent in multi-domain amnestic mild cognitive impairment subtypes.
Psychogeriatrics. 2014 Mar;14(1):63-71. doi: 10.1111/psyg.12042. Epub 2014 Feb 16.
6
A Comparison of Serial Position Effects in Patients with Mild Cognitive Impairment due to Parkinson's Disease or to Alzheimer's Disease.
Dement Geriatr Cogn Disord. 2020;49(2):170-178. doi: 10.1159/000507757. Epub 2020 Jul 7.
7
Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease.
Geriatr Gerontol Int. 2015 Aug;15(8):961-8. doi: 10.1111/ggi.12374. Epub 2014 Sep 20.
8
Extent and neural basis of semantic memory impairment in mild cognitive impairment.
J Alzheimers Dis. 2012;28(4):823-37. doi: 10.3233/JAD-2011-110989.
9
Distinctive neuropsychological profiles differentiate patients with functional memory disorder from patients with amnestic-mild cognitive impairment.
Acta Neuropsychiatr. 2018 Apr;30(2):90-96. doi: 10.1017/neu.2017.21. Epub 2017 Jul 17.
10
Absence of a relationship between subjective memory complaint and objective memory impairment in mild cognitive impairment (MCI): is it time to abandon subjective memory complaint as an MCI diagnostic criterion?
Int Psychogeriatr. 2012 Sep;24(9):1505-14. doi: 10.1017/S1041610212000695. Epub 2012 May 1.
引用本文的文献
1
Alzheimer's Disease: In Vitro and In Vivo Evidence of Activation of the Plasma Bradykinin-Forming Cascade and Implications for Therapy.
Cells. 2024 Dec 10;13(24):2039. doi: 10.3390/cells13242039.
2
Innate neuroimmunity across aging and neurodegeneration: a perspective from amyloidogenic evolvability.
Front Cell Dev Biol. 2024 Jul 12;12:1430593. doi: 10.3389/fcell.2024.1430593. eCollection 2024.
3
Cross-platform proteomics signatures of extreme old age.
Geroscience. 2025 Feb;47(1):1199-1220. doi: 10.1007/s11357-024-01286-x. Epub 2024 Jul 25.
4
Cross-platform proteomics signatures of extreme old age.
bioRxiv. 2024 Apr 14:2024.04.10.588876. doi: 10.1101/2024.04.10.588876.
5
A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease.
Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2309389120. doi: 10.1073/pnas.2309389120. Epub 2023 Aug 28.
6
Vascular Dysfunction in Alzheimer's Disease: Alterations in the Plasma Contact and Fibrinolytic Systems.
Int J Mol Sci. 2023 Apr 11;24(8):7046. doi: 10.3390/ijms24087046.
7
Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers' Case-Control Study.
Pharmaceutics. 2023 Mar 12;15(3):924. doi: 10.3390/pharmaceutics15030924.
8
Development of a Gastrointestinal-Myoelectrical-Activity-Based Nomogram Model for Predicting the Risk of Mild Cognitive Impairment.
Biomolecules. 2022 Dec 12;12(12):1861. doi: 10.3390/biom12121861.
9
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms.
Res Pract Thromb Haemost. 2022 Oct 13;6(7):e12815. doi: 10.1002/rth2.12815. eCollection 2022 Oct.
10
Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease.
Biomedicines. 2022 Aug 4;10(8):1890. doi: 10.3390/biomedicines10081890.
本文引用的文献
1
Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients.
Neurobiol Dis. 2020 Jun;139:104833. doi: 10.1016/j.nbd.2020.104833. Epub 2020 Mar 12.
2
An antibody against HK blocks Alzheimer's disease peptide β-amyloid-induced bradykinin release in human plasma.
Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):22921-22923. doi: 10.1073/pnas.1914831116. Epub 2019 Oct 28.
3
Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.
J Am Coll Cardiol. 2019 Oct 15;74(15):1910-1923. doi: 10.1016/j.jacc.2019.07.081.
4
Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models.
Nat Neurosci. 2019 Mar;22(3):413-420. doi: 10.1038/s41593-018-0329-4. Epub 2019 Feb 11.
5
Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model.
Neuron. 2019 Mar 20;101(6):1099-1108.e6. doi: 10.1016/j.neuron.2019.01.014. Epub 2019 Feb 5.
6
A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment.
Alzheimers Dement (Amst). 2018 Aug 4;10:480-489. doi: 10.1016/j.dadm.2018.06.008. eCollection 2018.
7
Blood will out: vascular contributions to Alzheimer's disease.
J Clin Invest. 2018 Feb 1;128(2):556-563. doi: 10.1172/JCI97509.
8
Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.
Nat Rev Neurol. 2018 Mar;14(3):133-150. doi: 10.1038/nrneurol.2017.188. Epub 2018 Jan 29.
9
Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging.
Sci Rep. 2017 Nov 1;7(1):14849. doi: 10.1038/s41598-017-13951-7.
10
Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice.
Blood. 2017 May 4;129(18):2547-2556. doi: 10.1182/blood-2016-11-753202. Epub 2017 Feb 27.
Zotero 插件